Page 12 - சந்தை தயாரித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

20.12.2020 Valneva: Valneva SE, an Austrian/french specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe. The VLA2001-201 study is a randomized, double blind trial evaluating the safety and immunogenicity for three dose levels in approximately 150 healthy adults. The study will be conducted in study sites across the United Kingdom and is supported by the National Institute for Health Research (NIHR). In September 2020, Valneva announced a major COVID-19 vaccine partnership with the U.K. government. Under the agreement, if vaccine development is successful, Valneva will provide the UK government wi

New yorkUnited statesNordrhein westfalenUnited kingdomMr dichtungstechnik gmbLang schwarzEuropean patent officeSemperit groupVienna stock exchangeNetworks segmentBaader bankBaader bank geschNational institute for health researchSemperit ag holdingNational instituteHealth research